UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Clinical trials for UNDIFFERENTIATED PLEOMORPHIC SARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNDIFFERENTIATED PLEOMORPHIC SARCOMA trials appear
Sign up with your email to follow new studies for UNDIFFERENTIATED PLEOMORPHIC SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boosts chemo against rare sarcomas?
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and w…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE2 • Sponsor: Alexander Z. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental combo shows promise for rare sarcomas
Disease control CompletedThis early-phase study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine) is safe for people with two rare types of soft tissue sarcoma (leiomyosarcoma and undifferentiated pleomorphic sarcoma). Twenty-five adults with advanced or in…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo shows promise for rare cancers
Disease control CompletedThis study tested a combination of two drugs—pembrolizumab (an immunotherapy) and cyclophosphamide (a chemotherapy)—in 129 people with advanced sarcomas that had spread or could not be removed by surgery. The goal was to see if the combination could shrink tumors or stop them fro…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Personalized chemo shows promise against rare sarcomas
Disease control CompletedThis Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE3 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental drug combo targets Hard-to-Treat sarcomas
Disease control CompletedThis study tested a new drug called mecbotamab vedotin, alone or with the immunotherapy nivolumab, in 245 adults and teens aged 12+ with advanced solid tumors, including sarcomas. The goal was to check safety and see if the drug shrinks tumors. The trial is now complete, and resu…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE1, PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a simple test predict who will respond to this sarcoma drug?
Knowledge-focused CompletedThis study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: NA • Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC